Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinven’s portfolio company Partner in Pet Food in connection with its acquisition of the Doggy
Mandate

Vinge advises Cinven’s portfolio company Partner in Pet Food in connection with its acquisition of the Doggy

July 08, 2020 EU, Competition and Regulatory Employment and Benefits IT, Telecommunications and Outsourcing Banking and Finance M&A Corporate Commercial

Vinge advises Cinven’s portfolio company Partner in Pet Food, a leading European pet food manufacturer, in connection with its acquisition of the Doggy Group (“Doggy”).

Doggy is a leading Swedish pet food producer and distribution with well-known brands such as Doggy, Mjau and Bozita. The acquisition will complement Partner in Pet Food's product range, geographical markets and distribution channels.

The transaction is conditional upon customary approvals by competition authorities.

Vinge’s team mainly consisted of partner Christina Kokko and associates Carl Sander, Hannah Kajlinger and Jonathan Riddersholm (M&A), Christoffer Nordin and Ellinor Wargenbrant (Corporate Commercial), Olof Löfvenberg (Environment & Permits), Axel Jansson and Felix Möller (Banking & Finance), Lisa Ullman and Ebba Svenburg (Employment), Karl-Hugo Engdahl (IT), Xandra Ståhlberg and Lisa Malmborg (Antitrust) and VDR-assistant Carl Bruneheim.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025